| Bioactivity | CGP 35348 is a selective, brain penetrant, centrally active GABAB receptor antagonist with an EC50 of 34 μM. CGP 35348 shows affinity for the GABAB receptor only[1]. CGP 35348 has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage[2]. | ||||||||||||
| In Vivo | CGP 35348 enhances non-REM sleep and rapid eye movement (REM) sleep and reduces strongly spike-wave discharges[3]. Animal Model: | ||||||||||||
| Name | CGP35348 | ||||||||||||
| CAS | 123690-79-9 | ||||||||||||
| Formula | C8H20NO4P | ||||||||||||
| Molar Mass | 225.22 | ||||||||||||
| Appearance | Oil | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. H R Olpe,et al. CGP 35348: a centrally active blocker of GABAB receptors. CGP 35348: a centrally active blocker of GABAB receptors [2]. Q Gillani, et al. CGP 35348, GABA B receptor antagonist, has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage. Biomed Res Int. 2014;2014:295215. [3]. A Puigcerver, et al. Effects of the GABAB antagonist CGP 35348 on sleep-wake states, behaviour, and spike-wave discharges in old rats. Brain Res Bull. 1996;40(3):157-62. |